NCT00172029 2023-08-18
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
Novartis
Phase 4 Completed
Clinical Trials
23 trialsNCT00622505 2021-05-26
Z-MARK
Novartis
Phase 4 Completed
NCT00063609 2017-09-13
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
Novartis
Phase 4 Completed
NCT00171964 2017-06-01
Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions
Novartis
Phase 4 Completed
NCT00219271 2017-05-31
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
Novartis
Phase 4 Completed
NCT00241111 2017-03-06
Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis
Novartis
Phase 4 Completed
NCT00434447 2017-02-27
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00237146 2017-02-23
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
Novartis
Phase 4 Completed
NCT00242554 2017-02-23
Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
Novartis
Phase 4 Completed
NCT00434317 2017-02-23
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00334139 2017-02-07
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
Novartis
Phase 4 Completed
NCT00172003 2016-11-18
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
Novartis
Phase 4 Completed
NCT00391690 2016-11-18
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
Novartis
Phase 4 Completed
NCT00219219 2015-04-14
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00242528 2015-04-14
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
Novartis
Phase 4 Withdrawn
NCT00333229 2014-11-25
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Novartis
Phase 4 Terminated
NCT01129336 2014-05-20
MACS1295
Novartis
Phase 4 Completed
NCT00172016 2012-04-30
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
Novartis
Phase 4 Completed
NCT00029224 2012-02-01
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Novartis
Phase 4 Completed
NCT00104104 2011-06-29
A Multiple Myeloma Trial in Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00237159 2011-03-23
Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
Novartis
Phase 4 Completed
NCT00035997 2009-11-23
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
Novartis
Phase 4 Completed
NCT00099541 2009-11-23
Non-small Cell Lung Cancer Registry
Novartis
Phase 4 Completed